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Adaptive designs allow planned modifications based on data accumulating within a study. The promise of greater
flexibility and efficiency stimulates increasing interest in adaptive designs from clinical, academic, and regulatory
parties. When adaptive designs are used properly, efficiencies can include a smaller sample size, a more efficient
treatment development process, and an increased chance of correctly answering the clinical question of interest.
However, improper adaptations can lead to biased studies. A broad definition of adaptive designs allows for
countless variations, which creates confusion as to the statistical validity and practical feasibility of many designs.
Determining properties of a particular adaptive design requires careful consideration of the scientific context and
statistical assumptions. We first review several adaptive designs that garner the most current interest. We focus on
the design principles and research issues that lead to particular designs being appealing or unappealing in
particular applications. We separately discuss exploratory and confirmatory stage designs in order to account for the
differences in regulatory concerns. We include adaptive seamless designs, which combine stages in a unified
approach. We also highlight a number of applied areas, such as comparative effectiveness research, that would
benefit from the use of adaptive designs. Finally, we describe a number of current barriers and provide initial
suggestions for overcoming them in order to promote wider use of appropriate adaptive designs. Given the
breadth of the coverage all mathematical and most implementation details are omitted for the sake of brevity.
However, the interested reader will find that we provide current references to focused reviews and original
theoretical sources which lead to details of the current state of the art in theory and practice.
Keywords: Adaptive designs, Flexible designs, Group sequential, Internal pilot, Power, Sample size re-estimation,
Comparative effectiveness research, Small clinical trialsReview
Introduction
In traditional clinical trials, key elements such as pri-
mary endpoint, clinically meaningful treatment differ-
ence, and measure of variability are pre-specified during
planning in order to design the study. Investigators then
collect all data and perform analyses. The success of the
study depends on the accuracy of the original assump-
tions. Adaptive Designs (ADs) give one way to address
uncertainty about choices made during planning. ADs
allow a review of accumulating information during a trial
to possibly modify trial characteristics [1]. The flexibility
can translate into more efficient therapy development by* Correspondence: johnkair@ufl.edu
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reproduction in any medium, provided the orreducing trial size. The flexibility also increases the chance
of a ‘successful’ trial that answers the question of interest
(finding a significant effect if one exists or stopping the
trial as early as possible if no effect exists).
ADs have received a great deal of attention in the statis-
tical, pharmaceutical, and regulatory fields [1-8]. The rapid
proliferation of interest and inconsistent use of termin-
ology has created confusion and controversy about simi-
larities and differences among the various techniques.
Even the definition of an ‘adaptive design’ is a source of
confusion. Fortunately, two recent publications have
reduced the confusion. An AD working group was formed
in 2005 in order to ‘foster and facilitate wider usage and
regulatory acceptance of ADs and to enhance clinical de-
velopment, through fact-based evaluation of the benefits
and challenges associated with these designs’ [2]. The
group was originally sponsored by the PharmaceuticalLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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currently sponsored by the Drug Information Association.
The group defined an AD as ‘a clinical study design that
uses accumulating data to decide how to modify aspects
of the study as it continues, without undermining the val-
idity and integrity of the trial.’ The group also stressed that
the changes should not be ad hoc, but ‘by design.’ Finally,
the group emphasized that ADs are not a solution for
inadequate planning, but are meant to enhance study effi-
ciency while maintaining validity and integrity. Subse-
quently, the US Food and Drug Administration (FDA)
released a draft version of the “Guidance for Industry:
Adaptive Design Clinical Trials for Drugs and Biologics”
[3]. The document defined an AD as ‘a study that includes
a prospectively planned opportunity for modification of
one or more specified aspects of the study design and hy-
potheses based on analysis of data (usually interim data)
from subjects in the study.’ Both groups supported the no-
tion that changes are based on pre-specified decision
rules. However, the FDA defined ADs more generally by
interpreting as ‘prospective’ any adaptations planned ‘be-
fore data were examined in an unblinded manner by any
personnel involved in planning the revision’ [3]. Since dif-
ferent individuals become unblinded (that is, ‘unmasked’)
at different points in a trial, we believe the FDA draft guid-
ance document left open doors to some gray areas that
merit further discussion. Both groups made it clear that
the most valid ADs follow the principle of ‘adaptive by de-
sign’ since that is the only way to ensure that the integrity
and validity of the trial are not compromised by the
adaptations.
It is important to differentiate between ADs and what
others have referred to as flexible designs [1,9]. The differ-
ence was perhaps best described by Brannath et al. who
state, that ‘Many designs have been suggested which in-
corporate adaptivity, however, are in no means flexible,
since the rule of how the interim data determine the de-
sign of the second part of the trial is assumed to be com-
pletely specified in advance’ [9]. Thus, a flexible design
describes a more general type of study design that incor-
porates both planned and unplanned features (Figure 1).
There is general agreement that the implementation of
flexible designs cannot be haphazard but must preserve
validity and integrity (for example, by controlling type I
error rate). While attractive, we believe that this flexibility
opens a trial to potential criticism from outside observers
and regulators. Furthermore, we believe that many of the
concerns could be eliminated by giving more thought to
potential adaptations during the planning stages of a trial.
Correspondingly, for this review, we adopt a definition
similar to that of the AD working group and of the FDA
and focus only on ADs that use information from within-
trial accumulating data to make changes based on pre-
planned rules.As Figure 1 demonstrates, even the constrained defin-
ition of AD allows a wide range of possible adaptations,
some more acceptable than others. The designs allow
updates to the maximum sample size, study duration,
treatment group allocation, dosing, number of treatment
arms, or study endpoints. For each type of adaptation,
researchers must ensure that the type I error rate is con-
trolled, the trial has a high probability of answering the
research question of interest, and equipoise is main-
tained [10]. New analytic results with properly designed
simulations [11] are often needed to meet the restric-
tions. The approach reinforces the importance of ‘adap-
tive by design’ because the adaptation rules must be
clearly specified in advance in order to properly design
the simulations.
Despite their suggested promise, current acceptance
and use of ADs in clinical trials are not aligned with the
attention given to ADs in the literature. In order to jus-
tify the use of ADs, more work is needed to clarify which
designs are appropriate, and what needs to be done to
ensure successful implementation. In the remainder of
the paper we summarize specific AD types used in clin-
ical research and address current concerns with the use
of the designs. There are too many possible ADs to
cover all of them in a brief review. We begin with learn-
ing stage designs. Next, we describe confirmatory stage
designs. We then discuss adaptive seamless designs that
seek to integrate multiple stages of clinical research into
a single study. Next we explore applied areas that would
benefit from ADs. Finally, we describe some barriers to
the implementation of ADs and suggest how they can be
resolved in order to make appropriate ADs practical.
Learning-stage adaptive designs
Overview
In general, AD methods are accepted more in the learn-
ing (exploratory) stages of clinical trials [3,4]. Early in
the clinical development process ADs allow researchers
to learn and optimize based on accruing information
related to dosing, exposure, differential participant re-
sponse, response modifiers, or biomarker responses [3].
The low impact of exploratory studies on regulatory ap-
proval means less emphasis on control of type I errors,
and more emphasis on control of type II errors (avoiding
false negatives). Early learning phase designs in areas
with potentially toxic treatments (for example, cancer or
some neurological diseases) seek to determine the max-
imum tolerated dose (MTD), the highest dose for less
than some percent of treated participants (such as 33 or
50 percent) having dose-related toxicities. An accurate
determination of the MTD is critical since it will likely
be used as the maximum dose in future clinical develop-
ment. If the dose is too low, a potentially useful drug
could be missed. If the dose is too high, participants in




















Figure 1 Summary of different types of adaptive designs for clinical trials.
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been determined, the next step is typically to choose a
dose (less than or equal to the MTD) most likely to
affect the clinical outcome of interest. Since the issues
are very different for these two phases of the learning
stage, we briefly summarize each below.
Early learning stage (toxicity dose)
Although a number of methods have been proposed for
phase I MTD determination, by far the most prevalent is
the traditional 3 + 3 method originally developed for, and
primarily used in, oncology trials [12,13]. In this rule-
based method, toxicity is defined as a binary event and
participants are treated in groups of three, starting with
an initial low dose. The algorithm then iterates, moving
dose levels up or down depending on the number of
toxicities observed. The MTD is identified from the data;
for example, the highest dose studied with less than 1/3
toxicities (that is, zero or one dose-limiting toxicity out
of six participants). This method is straightforward and
convenient in that it requires no modeling and very few
assumptions. However, the method has been criticized
for not producing a good estimate [14]. Several adaptive
dose-response methods have advantages over the trad-
itional method. A popular design is the Bayesian adap-
tive model-based approach called the continual
reassessment method (CRM) [14]. By more effectively
estimating the MTD along with a dose-response curve,
the CRM tends to quickly accelerate participants to
doses around the MTD. Fewer participants are treated at
ineffective doses and the design is less likely to over-
estimate or under-estimate the true MTD compared to
the 3 + 3 method [14]. Safety concerns about the original
CRM led to several improvements [15,16]. The CRM
has utility in any area where finding the MTD is needed.However, to date, it has primarily been used in cancer
[17] and stroke [18,19] research trials.
Late learning stage exploratory (efficacy dose)
ADs for later exploratory development are not as well-
developed as for earlier work. Consequently, PhRMA
created a separate adaptive dose response working group
to explore the issue and make recommendations [20].
Among the group’s conclusions were that dose response
(DR) is more easily detected than estimated, typical sam-
ple sizes in dose-ranging studies are inadequate for DR
estimation, and adaptive dose-ranging methods clearly
improve DR detection and estimation. The group also
noted the advantages of design-focused adaptive meth-
ods. The group favored a general adaptive dose alloca-
tion approach using Bayesian modeling to identify an
appropriate dose for each new participant based on pre-
vious responses [21], as employed in the Acute Stroke
Therapy by Inhibition of Neutrophils (ASTIN) study
[22]. Unfortunately, complex simulations (or new ana-
lytic development) and software are needed in order to
control the operating characteristics and employ the
methods. The development of well documented and
user-friendly software is vital for future use. We believe
that access to dependable and easy-to-use software will




From the FDA’s current perspective, some designs are
considered ‘well understood,’ while others are not [3].
Accordingly, scrutiny of a protocol will vary depending
on the type of design proposed. The FDA generally
accepts study designs that base adaptations on masked
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recruitment criteria based on accruing aggregate base-
line measurements. Group sequential (GS) designs are
also deemed ‘well understood’ by the FDA. GS designs
allow stopping a trial early if it becomes clear that a
treatment is superior or inferior. Thus, GS methods
meet our definition of an AD and are by far the most
widely used ADs in modern confirmatory clinical re-
search. They have been extensively described elsewhere
[23] and will not be discussed further.
Some designs are ‘less well understood,’ from the FDA
perspective [3]. It is important to note that such meth-
ods are not automatically prohibited by the FDA. Rather,
there is a higher bar for justifying the use of less well-
understood designs. Proving lack of bias and advanta-
geous operating characteristics requires extensive plan-
ning and validation. Debate continues concerning the
usefulness and validity of confirmatory ADs in the cat-
egory. Examples include adaptive randomization, enrich-
ment designs, and sample size re-estimation (although
some subtypes are classified as ‘well understood’). We
briefly mention each below.
Adaptive randomization
Traditional randomization fixes constant allocation prob-
abilities in advance. Adaptive randomization methods vary
the allocation of subjects to treatment groups based on ac-
cruing trial information [1,24,25]. There are two basic
types: covariate and response adaptive randomization.
Each is briefly described immediately below.
With a sufficient sample size, a traditional randomization
process will balance the distribution of all known and un-
known covariates at the end of a study. This is, in fact,
one of the major benefits of randomization. However, this
process does not ensure that the covariates are balanced
at all times during the conduct of the trial. Covariate
adaptive randomization provides a higher probability of
having treatment group balanced covariates during the
study by allowing the allocation probabilities to change as
a function of the current distribution of covariates. Meth-
ods exist forcing optimum balance deterministically (for
example, minimization), with fixed (unequal) probability,
and with dynamic allocation probabilities [26]. A number
of examples of methods and practice can be found in the
literature (for example, [27,28]).
Alternatively, response adaptive randomization uses
observed treatment outcomes from preceding partici-
pants to change allocation probabilities. The strategy can
fulfill the ethical desire to increase the likelihood of giv-
ing an individual the best-known treatment at the time
of randomization. Use is not widespread, but examples
can be found [29-32]. Although attractive, response
adaptive randomization schemes have administrative
complexities and may create ethical dilemmas [7,33].One complication is that enrolling later in the study
increases the chance of receiving the superior treatment
since the randomization probability will have increased
for the better treatment. Thus, bias can be created if
sicker patients enroll earlier and healthier ones decide to
wait until later to enroll [5]. Furthermore, the actual
advantages may be negligible since the analysis, type I
error rate control, and sample size calculations become
more complicated due to the need to account for adap-
tive randomization [34-36]. Proponents of response-
adaptive randomization designs defend their efficiency and
usefulness while continuing to address criticisms with new
methods and simulation results [25]. However, according
to the FDA draft guidance, ‘Adaptive randomization should
be used cautiously in adequate and well-controlled studies,
as the analysis is not as easily interpretable as when fixed
randomization probabilities are used’ [3].
Enrichment designs
Enrichment of a study population refers to ensuring that
participants in a trial are likely to demonstrate an effect
from treatment, if one exists [37]. For example, there is
benefit to enrolling participants lacking comorbidities,
with a risk factor of interest (such as high blood pres-
sure), and likely to be compliant. An extension known as
adaptive enrichment designs fulfills the desire to target
therapies to patients who can benefit the most from the
treatment [38,39]. In such designs, a trial initially consid-
ers a broad population. The first study period reveals
participant groups most likely to benefit from the test
agent (discovery phase). Subgroup members are then
randomized to receive either the active agent or control
(validation phase). Power for the chosen subgroups is
increased due to the increased sample size in the sub-
groups, while non-promising groups are discarded.
Adaptive enrichment designs have been praised for their
ability to identify patient groups and undiluted effect
sizes that can aid in the design and efficiency of replica-
tion studies [39]. An appealing area for adaptive enrich-
ment is pharmacogenetic research where it could allow
for isolation of the one or two genetic marker subgroups
that are predictive for treatment response. The approach
can increase efficiency when identifiable genetic sub-
groups have increased treatment benefit [40]. Addition-
ally, some studies have used an adaptive enrichment to
identify a subset most likely to respond to treatment
[41]. However, adaptive enrichment designs have been
criticized as having unfavorable operating characteristics
in real-world confirmatory research. Disadvantages in-
clude increases in complexity, biased treatment effect
estimates, lack of generalizability, and lack of informa-
tion in excluded groups [7]. We believe that adaptive en-
richment designs currently have greatest value in late
learning stage designs.
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Choosing a fixed sample size is complicated by the need to
choose a clinically meaningful treatment effect and to spe-
cify values for nuisance parameters such as the variance,
overall event rate, or accrual rate. Inaccurate estimates of
the parameters lead to an underpowered or overpowered
study, both of which have negative consequences. Sample
size re-estimation (SSR) designs allow the parameter esti-
mates to be updated during an ongoing trial, and then
used to adjust the sample size accordingly [42].
Historically, a great deal of controversy surrounding
ADs has centered on SSR based on observed treatment
effects [43-45]. The methods are defended for use in
specific contexts, such as using a small amount of initial
funding to seek promising results [46]. The authors of
the FDA draft guidance document, in listing the design
as ‘less well understood,’ noted the potential for ineffi-
ciency, an increased type I error rate, difficulties in inter-
pretation, and magnification of treatment effect bias [3].
A major concern with this type of SSR design is the po-
tential to convey treatment effect information from deci-
sions made using treatment-arm specific data at interim
time points. A clever investigator with knowledge of the
SSR procedure and the decision made after viewing the
data could possibly back-calculate an absolute treatment
effect. It should be noted that concerns of gaining some
knowledge based on an action (or inaction) exist when
using any treatment-arm specific data, including GS
methods. Nevertheless, the clinical trials community
now routinely uses GS methods without major concerns
since the conveyed information is usually minimal.
Other types of SSR have stimulated less controversy. For
example, internal pilots (IPs) are two stage designs with
no interim testing, but with interim SSR based only on
first stage nuisance parameter estimates [47]. Moderate to
large sample sizes imply minimal type I error rate inflation
with unadjusted tests in a range of settings [4,48,49]. IP
designs can be used in large randomized controlled trials
to re-assess key nuisance parameters and make appropri-
ate modifications with little cost to type I error rate. In
contrast, small IP trials can have inflated type I error rate
and therefore require adjustments for bias [50-52]. Since
IP designs do not include interim testing or effect size
based SSR, there generally are not the same concerns
about indirectly conveying an absolute treatment effect,
though Proschan showed that it is possible if a researcher
has knowledge of both the IP procedure and access to the
blinded data [48]. Consequently, some observers believe
that, from a regulatory standpoint, IP methods that keep
group allocation masked may be preferred whenever pos-
sible. Accordingly, masked methods for IPs have been pro-
posed [53,54] and are classified as ‘well understood’ in the
FDA Draft Guidance document [3]. However, unmasked
IP procedures may be appropriate provided that steps aretaken to minimize the number of people with access to
data or to the group allocation. Whether blinded or not, if
an IP design is implemented in a setting where non-
objective parties do not have access to accumulating raw
data, the sample size changes will give no information
concerning effect trends of interest. Thus, we believe that
the setting has fewer risks and therefore encourage more
use of SSR based on nuisance parameters in future phase
II and III trials.
Adaptive seamless designs
A seamless design combines exploratory and confirma-
tory phases into a single trial. As a type of two-stage de-
sign, seamless designs can increase overall efficiency by
reducing the lead time (‘white space’) between phases.
Information from participants enrolled in the first stage
is used to inform the second stage. An adaptive seamless
design proceeds in the same manner, but uses data from
participants enrolled in both stages in the final analysis.
Previous authors have paid the most attention to a
seamless transition between phase IIb (learning) and
phase III (confirming) [1,55-58]. Seamless designs also
seem appealing in early development (phase I/IIa). The
approach allows for a more efficient utilization of sample
size and resources versus conducting completely separ-
ate studies. However, since data from the learning phase
inform decisions for the second phase, using the data in
the final analysis raises concerns about bias and error
rate inflation. As an example, consider the Coenzyme
Q10 in Amyotrophic Lateral Sclerosis (QALS) study: an
adaptive, two-stage, randomized controlled phase I/IIa
trial to compare decline in Amyotrophic Lateral Scler-
osis (ALS) Functional Rating Scale score [59]. The first
phase used a selection design [60] to choose one of two
doses (1800 mg or 2500 mg). The second phase then
compared the selected dose to placebo using a futility
design [61]. Because the second phase dose was selected
as ‘best’ in the first phase, there is a positive bias carried
forward. Correspondingly, if the final test does not ac-
count for the bias, the overall type I error rate may be
increased. The QALS investigators performed a series of
studies to determine a bias correction and incorporated
it into the final test statistic [62]. The scenario is com-
mon since seamless designs require special statistical
methods and extra planning to account for the potential
bias. In general, the potential benefits must be weighed
against the additional effort required to ensure a valid
test at the end of the study.
Applied areas that would benefit from adaptive designs
Combinations of group sequential and sample size
re-estimation
Combining the power benefits of an IP design and the
early stopping sample size advantages of GS designs has
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monitoring approaches for simultaneous use of GS and
IP methods in large clinical trials have been proposed
[63]. The approach can give power and expected sample
size benefits over fixed sample methods in small sam-
ples, but may inflate the type I error rate [64]. Kairalla
et al. [65] provided a practical solution; however, more
work is needed in the area.
Rare diseases and small trials
Planning a small clinical trial, particularly for a rare dis-
ease, presents several challenges. Any trial should exam-
ine an important research question, use a rigorous and
sensitive methodology to address the question, and
minimize risks to participants. Choosing a feasible study
design to accomplish all of the goals in a small trial can
be a formidable challenge. Small trials exhibit more vari-
ability than larger trials, which implies that standard
designs may lead to trials with power adequate only for
large effects. The setting makes ADs particularly appeal-
ing. However, it is important to be clear about what an
AD can and cannot do in the rare disease setting. Most
importantly, an AD cannot make a drug more effective.
One of the biggest benefits of an AD is quite the oppos-
ite: identifying ineffective treatments earlier. Doing so
will minimize the resources allocated to studying an in-
effective treatment and allow re-distributing resources to
more promising treatments. Although ADs cannot
‘change the answer’ regarding the effectiveness of a par-
ticular treatment, they can increase the efficiency in
finding an answer.
Comparative effectiveness trials
Comparative effectiveness (CE) trials compare two or
more treatments [66] that have already been shown to
be efficacious. Unique issues found in CE trials make
ADs attractive in the area. For one, the concept of a
‘minimum clinically meaningful effect’ in the population
has a diminished meaning in a CE trial. Assuming
roughly equal costs and side effects, a range of values
may be identified with upper limit the largest reasonable
effect and lower limit the smallest effect deemed sizable
enough to change practice in the study context. Unfortu-
nately, since detecting smaller effects requires larger
sample sizes, for practical reasons researchers may feel
the need to power CE trials for effects on the upper end
of the spectrum. A potential AD could have two stages
with the first powered to detect the larger reasonable
effect size. At the conclusion of the first stage, one of
three decisions might be reached: 1) Declare efficacy
(one treatment best); 2) Declare futility (unlikely to show
difference between treatments); or 3) If evidence suggests
a smaller effect might exist, then proceed with a second
stage powered to detect the smaller effect. Another issueis that available variability estimates are probably too low
since the estimates were likely obtained from highly con-
trolled efficacy trials. If true, using the estimates to power
a CE trial may lead to an underpowered study. Thus,
variance-based SSR could be built into the prior example
to address the uncertainty. We believe ADs have promise
in CE trials and that future research is warranted.
Applications in other research settings
Currently, ADs are considered most often in the context
of clinical trials. However, the ability to modify incorrect
initial assumptions would have value in many other set-
tings. Importantly, since regulatory issues may not exist
in many research settings, we believe that ADs may
actually be much easier to implement. For example, la-
boratory research involving animals could use an AD to
re-assess key parameters and determine whether more
animals are needed to achieve high power. As another
example, an observational study requires assumptions
about the distribution of the population that will be en-
rolled. Any discrepancy between the hypothesized and
actual distribution of the enrolled population will affect
the power of the study. Although extensions of the IP
design to the observational setting have been considered
[67], more work is needed.
Barriers to implementing adaptive designs
Even though additional methodological development is
needed in ADs, appropriate statistical methods exist to
support a much greater use of ADs than currently seen.
We believe logistical issues and regulatory concerns, ra-
ther than statistical issues, currently limit AD use. The
majority of research on ADs has been driven by drug de-
velopment within the pharmaceutical industry. While
many basic principles remain the same regardless of the
funding environment, some specific challenges differ
when considering the use of ADs for trials funded by the
National Institutes of Health (NIH) or foundations. For
example, traditional funding mechanisms lack the
required flexibility to account for sample size modifica-
tions after initiation of a trial. There is also a general
sense of confusion and lack of understanding about the
distinction between acceptable and unacceptable adapta-
tions. If the reviewers do not understand the important
distinctions, a valid AD might not pass through peer re-
view. An NIH and private foundation funded workshop
on ‘Scientific Advances in Adaptive Clinical Trial Designs’
was held in November 2009, as a first attempt to address
the challenges [68]. Participants included representatives
from research institutions, regulatory bodies, patient advo-
cacy groups, non-profit organizations, professional asso-
ciations, and pharmaceutical companies. The participants
stressed that the use of ADs may require a different way
of thinking about the structure and conduct of Data and
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there is a great need for further education and communi-
cation regarding the strengths and weaknesses of various
types of ADs. For example, researchers should be encour-
aged to publish manuscripts describing experiences (both
positive and negative) associated with completed trials
that used an AD. Similarly, a stronger emphasis on a stat-
istical background for NIH reviewers and DSMB members
seems necessary.
While communication among parties can go a long way
towards increasing the use and understanding of ADs,
more work is needed to develop infrastructure to support
AD trials. Study infrastructure is one area where industry
is clearly ahead of grant funded research. As an example,
justifying properties of ADs often requires extensive plan-
ning through computations or simulations. Researchers
must find a way to fund the creation of extensive calcula-
tions for a hypothetical study. The issue is exacerbated by
fact that the planning is generally required prior to sub-
mitting a grant application for funding. Many pharma-
ceutical companies are developing in-house teams
primarily responsible for conducting such simulations.
Greater barriers exist for implementing the same type of
infrastructure within publicly funded environments, par-
ticularly given the challenges associated with the current
limited and highly competitive federal budget.
In our opinion, the most important way to ensure a
high chance of conducting a successful AD trial is to
have a high level of infrastructure (efficient data man-
agement, thorough understanding of AD issues, etcetera)
in place. A low complexity AD (for example, an IP or
GS design) conducted in a high infrastructure environ-
ment currently provides the best chance for success.
However, a low infrastructure environment might be
able to successfully conduct a low complexity AD, with a
little bit of extra effort. The same chance of success is
not present if one is trying to implement a high com-
plexity AD design (for example, an adaptive seamless II/
III design, or a combination of different adaptations).
With a complex design a high level of infrastructure is
needed in order to successfully conduct the trial. The
QALS study, a complex two-stage seamless design
described earlier, is a good example of a study with high
infrastructure and with high adaptivity [62]. The QALS
study was a success, requiring only 185 participants to
establish that the cost and effort of undertaking a phase
III trial would not be worthwhile. However, the trial was
successful only because all parties involved (researchers,
sponsor, DSMB members, etcetera) clearly understood
the intricacies of the AD being used. A break-down in
understanding for any stakeholder could have severely
damaged the study. A high complexity AD with low in-
frastructure is likely doomed to fail. Unfortunately, the
scenario is currently a common one due to the desire touse complex adaptive designs without the necessary high
level of infrastructure required for success. One solution
would be to only consider simple ADs. However, since
researchers are mainly interested in obtaining the effi-
ciency and advantages of more complex adaptations, we
believe that the only way to increase the chances for suc-
cess in the future is to first improve the existing infra-
structure. As previously stated, many companies have
begun the process. However, we believe that NIH should
also offer more recognition and funding for planning
clinical trials that might benefit from adaptations.
Although infrastructure characteristics often limit rates
of adaptation, a number of steps have been taken to
address the concern, especially in the neurosciences. One
ongoing example is the NIH and FDA supported ‘Acceler-
ating Drug and Device Evaluation through Innovative
Clinical Trial Design’ project [69]. The participants are
studying the development and acceptance of a wide range
of adaptive designs within the existing infrastructure of the
National Institute of Neurological Disorders and Stroke
(NINDS)-supported Neurological Emergencies Treatment
Trials (NETT) network [70]. The goal is to incorporate the
resulting designs into future network grant submissions.
Another example is the creation of the NINDS-funded
Network for Excellence in Neuroscience Clinical Trials
(NeuroNEXT) [71]. The goal of the network is to provide
infrastructure supporting phase II studies in neuroscience,
including the conduct of studies in rare neurological dis-
eases. The long-term objective of the network is to rapidly
and efficiently translate advances in neuroscience into
treatments for individuals with neurologic disorders. The
infrastructure is intended to serve as a model that can be
replicated across a number of studies and diseases. The
development of rich infrastructures such as NeuroNEXT
greatly increases the feasibility of using more novel trial
designs, including ADs. Additional infrastructure with flexi-
bility is needed in other disease areas to advance the use of
ADs, particularly in the publicly funded environment.
Conclusions
A general overview of the main design classes provides
the basis for discussing how to correctly implement ADs.
We agree with Vandemeulebroecke [72] that discussion
concerning ADs should center on five main points: feasi-
bility, validity, integrity, efficiency, and flexibility. We rec-
ommend systematically addressing each of the concerns
through the development of better methodology, infra-
structure, and software. Successful adoption of ADs also
requires systematic changes to clinical research policies.
We believe that the barriers can be overcome to move ap-
propriate ADs into common clinical practice.
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